Updates on Device-Based Therapies for Patients with Heart Failure
- 425 Downloads
Purpose of Review
Heart failure is a growing epidemic. Optimal medical therapy remains the cornerstone of heart failure management but device-based therapies have been shown to contribute to morbidity and mortality reduction.
Multiple investigational trials had been conducted in the past decade that helped us better understand and manage heart failure. In this manuscript, we will discuss the major device related trials of year 2017 in the fields of defibrillators, hemodynamic monitoring, remote monitoring, autonomic nervous system modulation, ventricular assist devices, and device-based valvular heart disease management.
Further research and trials in device-based therapies are needed to explore their long-term reduction in mortality and morbidity along with cost-effectiveness analyses in patients living with heart failure.
KeywordsDevice-based therapies Heart failure reduced ejection fraction Clinical trials CRT-D Hemodynamic monitoring LVAD
Compliance with Ethical Standards
Conflict of Interest
Jad Al Danaf and Amin Yehya declare no conflicts of interest.
Javed Butler has received research support from the National Institutes of Health, PCORI and the European Union; and serves as a consultant for Amgen, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squib, CVRx, G3 Pharmacautical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, StealthPeptide, SC Pharma, Vifor, and ZS Pharma.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology foundation/American Heart Association task force on practice guidelines developed in collaboration with the international society for heart and lung transplantation. J Am Coll Cardiol. 2009;53:e1–e90.CrossRefPubMedGoogle Scholar
- 5.Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. American Heart Association advocacy coordinating committee; council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular radiology and intervention; council on clinical cardiology; council on epidemiology and prevention; stroke council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–19.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology / American Heart Association Task force on clinical practice guidelines and the Heart Rhythm Society. Circulation.Google Scholar
- 11.Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautman S, Kim RJ, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online ahead of print October 30, 2017]. Circulation. 2017; https://doi.org/10.1161/CIR.0000000000000550.
- 12.• Zeilter EP, Friedman DJ, Daubert JP, Al-Khatib SM, Solomon SD, Biton Y, et al. Multiple comorbidities and response to cardiac resynchronization therapy: MADIT-CRT long-term follow-up. J Am Coll Cardiol. 2017;69(19):2369–79. This work presents long-term follow up of the landmark MADIT-CRT study showing the benefit of CRT-D versus ICD alone despite comorbidities. CrossRefGoogle Scholar
- 14.Skaf S, Thibault B, Khairy P, O’Meara E, Fortier A, Vakulenko HV, et al. Impact of left ventricular vs biventricular pacing on reverse remodeling: Insights from the evaluation of resynchronization therapy for heart failure (EARTH) trial. Can J Cardiol. 2017;33(10):1274–82.CrossRefPubMedGoogle Scholar
- 16.Biering-Sørensen T, Knappe D, Pouleur AC, Claggett B, Wang PJ, Moss AJ, et al. Regional longitudinal deformation improves prediction of ventricular tachyarrhythmias in patients with heart failure with reduced ejection fraction: A MADIT-CRT substudy. Circ Cardiovasc Imaging. 2017;10(1):e005096.CrossRefPubMedGoogle Scholar
- 19.Sapp JL, Parkash R, Wells GA, Yetisir E, Gardner MJ, Healey JS, et al. Cardiac resynchronization therapy reduces ventricular arrhythmias in primary but not secondary prophylactic implantable cardioverter defibrillator patients: insight from the resynchronization in ambulatory heart failure trial. Circ Arrhythm Electrophysiol. 2017;10(2):e004875.CrossRefPubMedGoogle Scholar
- 23.Gold MR, Aasbo JD, El-Chami MF, Niebauer M, Herre J, Prutkin JM, et al. Subcutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017;14(1):146–1463.Google Scholar
- 24.Boriani G, Da Costa A, Quesada A, Ricci RP, Favale S, Boscolo G, et al. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicenter randomized controlled trial. Eur J Heart Fail. 2017;19(3):416–25.CrossRefPubMedGoogle Scholar
- 27.• Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(15):1875–86. This work highlights the utility of an implantable safe device that allows PA pressure monitoring to reduce HF hospitalizations. CrossRefPubMedGoogle Scholar
- 29.Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P, et al. A transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I): a phase 2 randomized, sham-controlled trial. Circulation.Google Scholar
- 30.Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac hemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014;16:977–83.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. J Am Coll Cardiol Heart Fail. 2015;3:487–96.Google Scholar
- 35.Muller D, Remppis A, Schauerte P, Schmidt-Schweda S, Burkhoff S, Rousso B, et al. Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction. Clin Res Cardiol. 2017;106(11):893–904.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.• Mehra M, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376:440–50. This work shows that Heartmate 3 was associated with higher survival rates free of reoperation due to the lack of suspected or confirmed pump thrombosis. CrossRefPubMedGoogle Scholar
- 45.Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185.CrossRefPubMedGoogle Scholar